Suppliers / Finorga

Finorga

France Updated 9 July 2026

Finorga is an API manufacturer based in France. It holds 3 active US drug master files across a filed portfolio of 4 molecules. Its GMP standing is certified by ANSM (FR) and US FDA. Its most recent recorded inspection, by US FDA, closed on 27 February 2025 as VAI.

3
active US DMFs
0
valid CEPs
4
registered plants 2 with an FDA FEI number
1
filings across 1 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
2 of 2 confirmed
Inspections
8 of 8 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 27 February 2025 VAI US FDA
  • 24 November 2023 VAI US FDA
  • 20 September 2019 NAI US FDA
  • 22 June 2018 NAI US FDA
  • 23 September 2016 NAI US FDA
  • 30 May 2014 NAI US FDA
  • 13 December 2013 VAI US FDA
  • 2 June 2011 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
France, France 3002806990
Mourenx, France Not on file
Chasse Sur Rhone, France Not on file
France, France 3002806998

What they file, and where

Molecule Regulators Docs
Adapalene SFDA (Saudi Arabia), US FDA 2
Esmolol SFDA (Saudi Arabia), US FDA 2
Alizapride Hci SFDA (Saudi Arabia) 1
Icosapent Ethyl US FDA 1

Also appears on these molecule pages

Filings and GMP by regulator

Regulator Filings GMP certificates
MINSA (CR) 1 None
ANSM (FR) None 38
US FDA None 2

Comparing suppliers?

Choose your molecules and target markets. Finorga comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • 5 active litigation matters are on record.
  • The most recent inspection outcome was VAI, on 27 February 2025.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates